Table 4. Correlation between clinicopathological features and PAM pathway activation, PIK3CA mutation and PTEN loss.

	PAM activation		PIK3CA mutation		PTEN loss
Items	(146 cases)		(39 cases)		(98 cases)
	N (%)	P	N (%)	P	N (%)	P
Menopause
Yes	63(43.2%)	0.238	16(41.0%)	0.6	47(48.0%)	0.151
No	83(56.8%)		23(59.0%)		51(52.0%)
Tumor size (cm)
T1 (T≤2)	34(23.3%)	0.246	7(17.9%)	0.345	26(26.5%)	0.772
T2 (2<T≤5)	88(60.3%)		25(64.2%)		59(60.2%)
T3 or larger (T>5)	24(16.4%)		7(17.9%)		13(13.3%)
Lymph node involvement
Positive	82(56.2%)	0.906	23(59.0%)	0.487	51(52.0%)	0.376
Negative	64(43.8%)		16(41.0%)		47(48.0%)
Tumor grade
1	4(2.7%)	0.711	2(5.1%)	0.421	1(1.0%)	0.427
2	45(30.8%)		9(23.1%)		31(31.7%)
3	97(66.5%)		28(71.8%)		66(67.3%)
ER status
Positive	83(56.8%)	0.28	24(61.5%)	0.918	52(53.1%)	0.041
Negative	63(43.2%)		15(38.5%)		46(46.9%)
PR status
Positive	93(63.7%)	0.318	22(56.4%)	0.138	62(63.3%)	0.284
Negative	53(36.3%)		17(43.6%)		36(36.7%)
HER2 status
Positive	13(8.9%)	0.833	5(12.8%)	0.359	8(8.2%)	0.94
Negative	133(91.1%)		34(87.2%)		90(91.8%)
Unknown	0		0		0
Ki67 index
≥14%	107(73.3%)	0.438	32(82.1%)	0.174	74(75.5%)	0.269
<14%	39(26.7%)		7(17.9%)		24(24.5%)